{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:41:40Z","timestamp":1791290500902,"version":"4.3.0"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Tenofovir (TFV) is effective in preventing simian immunodeficiency virus (SIV) transmission in a macaque model, is available as the oral agent tenofovir disoproxil fumarate (TDF), and may be useful in the prevention of mother-to-child transmission of human immunodeficiency virus (HIV). We conducted a trial of TDF and TDF-emtricitabine (FTC) in HIV-infected pregnant women and their infants. Women received a single dose of either 600 mg TDF, 900 mg TDF, or 900 mg TDF-600 mg FTC at labor onset or prior to a cesarean section. Infants received no drug or a single dose of TDF at 4 mg\/kg of body weight or of TDF at 4 mg\/kg plus FTC at 3 mg\/kg as soon as possible after birth. All regimens were safe and well tolerated. Maternal areas under the serum concentration-time curve (AUC) and concentrations at the end of sampling after 24 h (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>24<\/jats:sub>\n            ) were similar between the two doses of TDF; the maximum concentrations of the drugs in serum (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ) and cord blood concentrations were higher in women delivering via cesarean section than in those who delivered vaginally (\n            <jats:italic>P<\/jats:italic>\n            = 0.04 and 0.046, respectively). The median ratio of the TFV concentration in cord blood to that in the maternal plasma at delivery was 0.73 (range, 0.26 to 1.95). Without TDF administration, infants had a median TFV concentration of 12 ng\/ml 12 h after birth. Following administration of a single dose of TDF at 4 mg\/kg, infant TFV concentrations fell below the targeted level, 50 ng\/ml, by 24 h postdose. In HIV-infected pregnant women and their infants, 600 mg of TDF is acceptable as a single dose during labor. Low concentrations at birth support infant dosing as soon after birth as possible. Rapidly decreasing TFV levels in infants suggest that multiple or higher doses of TDF will be necessary to maintain concentrations that are effective for viral suppression.\n          <\/jats:p>","DOI":"10.1128\/aac.00544-11","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T03:46:33Z","timestamp":1315367193000},"page":"5914-5922","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":60,"title":["Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants"],"prefix":"10.1128","volume":"55","author":[{"given":"Patricia M.","family":"Flynn","sequence":"first","affiliation":[{"name":"St. Jude Children's Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mirochnick","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Harvard School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Bardeguez","sequence":"additional","affiliation":[{"name":"University of Medicine and Dentistry of New Jersey, Newark, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rodman","sequence":"additional","affiliation":[{"name":"St. Jude Children's Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Robbins","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Huang","sequence":"additional","affiliation":[{"name":"Harvard School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Fiscus","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen K. A.","family":"Van Rompay","sequence":"additional","affiliation":[{"name":"University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Rooney","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kearney","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne M.","family":"Mofenson","sequence":"additional","affiliation":[{"name":"PAMA Branch, Eunice Kennedy Shriver National Institute for Child Health and Development, NIH, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Heather","family":"Watts","sequence":"additional","affiliation":[{"name":"PAMA Branch, Eunice Kennedy Shriver National Institute for Child Health and Development, NIH, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Jean-Philippe","sequence":"additional","affiliation":[{"name":"Henry Jackson Foundation, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Heckman","sequence":"additional","affiliation":[{"name":"Frontier Science &amp; Technology Research Foundation, Amherst, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edwin","family":"Thorpe","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cotter","sequence":"additional","affiliation":[{"name":"University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murli","family":"Purswani","sequence":"additional","affiliation":[{"name":"Bronx-Lebanon Hospital, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PACTG 394 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq447"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2733-2739.2001"},{"key":"e_1_3_2_4_2","volume-title":"Abstr. 15th Conf. Retrovir. Oppor. Infect.","author":"Best B. M.","year":"2008","unstructured":"BestB. M.. 2008. High-dose lopinavir and standard-dose emtricitabine pharmacokinetics during pregnancy and postpartum, abstr. 629. Abstr. 15th Conf. Retrovir. Oppor. Infect., Boston, MA."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007300951"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61605-5"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411033311801"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp900036s"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/499967"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200110190-00006"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000221686.67810.20"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/430742"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)80008-7"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.201"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00860-08"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01377-10"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/430741"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000638"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443090-00003"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181427835"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000172"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200306010-00006"},{"key":"e_1_3_2_24_2","volume-title":"Abstr. 16th Conf. Retrovir. Oppor. Infect.","author":"Mirochnick M.","year":"2009","unstructured":"MirochnickM.. 2009. Pharmacokinetics of tenofovir disoproxil fumarate after administration to HIV-1-infected pregnant women and their newborns, abstr. 940. Abstr. 16th Conf. Retrovir. Oppor. Infect., Montreal, Canada."},{"key":"e_1_3_2_25_2","volume-title":"Abstr. 11th Int. Workshop Clin. Pharmacol. HIV Ther.","author":"Mirochnick M.","year":"2010","unstructured":"MirochnickM.. 2010. Tenofovir disoproxil fumarate (TDF) pharmacokinetics (PK) with increased doses in HIV-1 infected pregnant women and their newborns (HPTN 057), abstr. 3. Abstr. 11th Int. Workshop Clin. Pharmacol. HIV Ther., Sorrento, Italy."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31815f3c23"},{"key":"e_1_3_2_27_2","volume-title":"Abstr. 18th Conf. Retrovir. Oppor. Infect.","author":"Nielsen-Saines K.","year":"2011","unstructured":"Nielsen-SainesK.. 2011. Phase III randomized trial of the safety and efficacy of 3 neonatal ARV regimens for prevention of intrapartum HIV-1 transmission: NICHD HPTN 040\/PACTG 1043, abstr. 124LB. Abstr. 18th Conf. Retrovir. Oppor. Infect., Boston, MA."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000931"},{"key":"e_1_3_2_29_2","unstructured":"Panel on Treatment of HIV-Infected Pregnant Women Prevention of Perinatal Transmission.\n14 September 2011 posting date. 2 November 2011 accession date. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Department of Health and Human Services NIH Bethesda MD. http:\/\/aidsinfo.nih.gov\/ContentFiles\/PerinatalGL.pdf."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318050d88c"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611283352201"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.7.1197"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199904010-00001"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832949d5"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833e1659"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199809000-00001"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1469-1487.2004"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000224972.60339.7c"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1998.14.761"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1086\/322781"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.4.1767-1774.2000"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.183-191.2004"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00544-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00544-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:21:25Z","timestamp":1645485685000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00544-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1128\/AAC.00544-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00544-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"2011-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-08-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}